Stem Cell Therapeutics Corp. Announces Presentations at Public Forum Discussing Stem Cell Therapies in Alberta

Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) announced today that Dr.
Samuel Weiss, Director of the Hotchkiss Brain Institute at the University of
Calgary, will be providing the keynote address and Dr. Allen Davidoff, VP
Product Development at SCT, will be a member of a response panel at the Alberta
Council of Technologies ("ABCtech") hosted event in Calgary, June 23, 2009, at
the Alberta Research Council. Dr Weiss' work founded SCT, and he remains a key
member of SCT's Scientific Advisory Board.


ABCtech is co-hosting back-to-back events in Edmonton and Calgary on June 22nd
and 23rd. In Edmonton, Dr. Martin Ferguson-Pell, Dean of the Faculty of
Rehabilitation Medicine of the University of Alberta, while in Calgary, Dr.
Samuel Weiss will demystify stem cell therapies and outline the vast
opportunities they represent to groups of diverse audiences including
policymakers, healthcare professionals, business entrepreneurs and the
interested general public.


The response panel consists of ethicists, investors, researchers and public
policy and rehabilitation specialists, who will discuss the dramatic
implications of stem cell therapies for treatment of degenerative diseases
associated with ageing, injury and lifestyle.


Both events are being co-hosted by the Alberta Council of Technologies and the
Alberta Health Industry Association and are being sponsored by Pfizer Inc. and
the Edmonton and Calgary Associations for Advanced Technology.


About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian
public biotechnology company (TSX VENTURE:SSS) focused on the development and
commercialization of drug-based therapies to treat central nervous system
diseases. SCT is a leader in the development of therapies that utilize drugs to
stimulate a patient's own resident stem cells. The Company's programs aim to
repair brain and nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual property supports
the potential expansion into future clinical programs in numerous neurological
diseases such as traumatic brain injury, multiple sclerosis, Huntington's
disease, Alzheimer's disease, and ALS.


These securities have not been registered under the United States Securities Act
of 1933, as amended, or the securities laws of any state, and may not be offered
or sold within the United States or to, or for the account or benefit of U.S.
persons unless an applicable exemption from U.S. registration requirements is
available.


Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.